David Einstein

Disease Group Leader, GU Medical Oncology @BIDMChealth @DanaFarber_GU, Asst Prof @harvardmed, dad, cyclist, Far Side superfan

[David Einstein @davidjeinstein]

@TylerSbrt Best leaf peeping year in a while!

[David Einstein @davidjeinstein]

@TylerSbrt @zklaassen_md @urotoday Yes! Unlikely we’ll get access to data anytime soon if there’s a registration submission, but sometimes can model based on publicly available data…

[David Einstein @davidjeinstein]

@urotoday @zklaassen_md @DKhalafMD @myESMO Seems like the question is how P->D vs D->P compare, not D vs P

[David Einstein @davidjeinstein]

@MarioTerlizziFR @PaulSargos @GenevieveLOOS12 @piet_ost @_ShankarSiva @PBlanchardMD @DrSpratticus Another case for the (eugonadal)TFS approach, including all patients from randomization!

[David Einstein @davidjeinstein]

@DrChoueiri @Dr_Aggen Strange results… 1 month PFS but 3 months OS benefit in a rapidly progressive disease… immediate separation of OS curves…

[David Einstein @davidjeinstein]

@Dr_Aggen @BrendanGuercio Like getting PSA to undetectable

[David Einstein @davidjeinstein]

@VincentRK @NEJM @eaonc @theNCI Amazing work! Time-to-event endpoints typically incentivize longer/more intensive treatment. Time to start using novel endpoints like Treatment-Free Survival to shift the incentives towards fixed duration or intermittent strategies, and reward drugs with durable off-tx effect?

[Jonathan Rosenberg MD @DrRosenbergMSK]

The MSKCC Genitourinary Oncology Service is looking for a motivated, patient-centered, clinical investigator with a focus on urothelial cancer. Join a great team focused on eradicating GU cancers!

https://t.co/vRUXraSPOB

[David Einstein @davidjeinstein]

Super insightful piece. With Daniel Sentana and @CaPsurvivorship, we’ve had similar debates re the meaning of healthcare contact days in advanced prostate cancer.

[Ramy Sedhom, MD, FASCO @ramsedhom]

"Ultimately, time is the most precious thing any person has—never more so than after a cancer diagnosis—and protecting how it is spent is a goal worth our shared effort."

Our piece - The commodification of Time Toxicity In Oncology
https://t.co/UhSEU8daxg

[David Einstein @davidjeinstein]

@TylerSbrt @AtishChoudhury @ChadTangMD @piet_ost @seanmmcbride @AmarUKishan @drdavidpalma @rweichselbaum @_ShankarSiva @jryckman3 @BarbaraJereczek @GiuliaMarvaso84 @GiulioFrancoli1 The challenge also is in interpreting any conditional endpoint, ie AMONG those recovering T, what are outcomes. Hence our approach for keeping all patients in the denominator from randomization.

[David Einstein @davidjeinstein]

@ggebraelmd @JAMANetworkOpen @PCFnews @urotoday @umangtalking @neerajaiims @montypal @DrChoueiri @AarmstrongDuke @OncHahn @Huntsman_GU @shilpaonc @EAntonarakis @PBarataMD @TiansterZhang Congrats and thanks for sharing! Do you think we’ll ever see an RCT or should the field move on to other questions?

[Tyler Seibert MD PhD @TylerSbrt]

@seanmmcbride @piet_ost @AmarUKishan @ChadTangMD @drdavidpalma @davidjeinstein @rweichselbaum @_ShankarSiva @jryckman3 @BarbaraJereczek @GiuliaMarvaso84 @GiulioFrancoli1 Fair points, nicely laid out.

With ADT, my top Q is: Does giving ADT now buy this patient sufficiently lower risk of something worse down the road?

If 6m ADT with MDT only delays need for ADT in the future, that’s not good enough. Needs to ⬇️death or ⬆️treatment-free survival.

[David Einstein @davidjeinstein]

It’s kaddo bourani day in clinic @FatimaKarzai

[David Einstein @davidjeinstein]

@BIDMC_CancerCtr @DeepaRangachari @BIDMC_HOFellows @ConquerCancerFd Congrats Kian!!

[BIDMC Cancer Center @BIDMC_CancerCtr]

🌟 Past and current @BIDMC_HOFellows presented at #ASCOQLTY26, including work led by @JRusheen implementing a BILH-wide tobacco screening and cessation referral program.

[David Einstein @davidjeinstein]

@ChadTangMD @piet_ost @seanmmcbride @AmarUKishan @drdavidpalma @rweichselbaum @TylerSbrt @_ShankarSiva @jryckman3 @BarbaraJereczek @GiuliaMarvaso84 @GiulioFrancoli1 Love the graphic! Similar challenges here & PROTEUS in determining whether hormonal therapy eradicates micromets or just suppresses them. If only there were some kind of approach to account for time on treatment now vs later… X-MET Treatment-Free Survival analysis coming soon!

[Amar Kishan @AmarUKishan]

Updated LUNAR analysis out in @EUplatinum. Now with a median follow-up of 32 months, exploratory analyses confirm the addition of 177Lu-PNT2002 to SBRT improves polymetastatic PFS (6 or more new lesion), castrate disease-free survival, and CT-based PFS (i.e., conventional MFS) https://t.co/qOiwvSSpbs

[David Einstein @davidjeinstein]

@urotoday @tranpt21 Common pitfall: equating PSMA+ BCR with metastatic disease. @Dr_RaviMadan @melissaabel20

[David Einstein @davidjeinstein]

Congrats!! What about AI for ebikes?

[BIDMC Department of Medicine @BIDMC_Medicine]

Incredibly proud of this partnership between @Google & our faculty, led by Drs. @AdamRodmanMD, Mark Cohen, Jacob Koshy & Peter Brodeur, to test AMIE, Google’s patient facing conversational AI tool, in the first-of-its-kind, real world clinical study with primary care patients! ⬇️

[David Einstein @davidjeinstein]

@TylerSbrt @felixfengmd @Sophia_KamranMD @HimanshuNagarMD @NRGonc @DrRanaMcKay @alison_tree @urotoday @OncoAlert @PCF_Science @ASTRO_org Our rad oncs will generally treat per SPPORT with +LNs and then require us to give ADT (although no 4th arm testing +LNs w/o ADT).